[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
September 5, 2012

The Safety Risks of InnovationThe FDA's Expedited Drug Development Pathway

Author Affiliations

Author Affiliations: Institute for Safe Medication Practices, Alexandria, Virginia (Mr Moore); and Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina (Dr Furberg).

JAMA. 2012;308(9):869-870. doi:10.1001/jama.2012.9658

Driving Biomedical Innovation” is one of the signature initiatives of the Obama Administration and of US Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg's tenure at the agency.1 This initiative embodies administration policies that government should encourage growth and innovation rather than being the stifling blanket of bureaucracy and delay so often cited by critics of government regulation. Prominent in the agency-wide initiative is the FDA's program for speeding approval of seemingly promising new drugs, known officially as the “Expedited Drug Development Pathway.”1

First Page Preview View Large
First page PDF preview
First page PDF preview
×